MAIN STORY
From scientific discovery to commercial leverage
International pharmaceutical groups increasingly look to Chinese laboratories to find promising additions to their development pipelines. AstraZeneca, GSK and Novo Nordisk are among the names involved in collaborations spanning cancer, obesity and other conditions. The trend suggests that innovation originating in China is attracting greater confidence, although promising early data cannot guarantee an approved medicine.
PharmCube data cited by Reuters Breakingviews put the potential total value of Chinese overseas licensing transactions at about $139.4 billion through October 8, compared with $138.8 billion for all of 2025. Upfront payments amounted to around $8 billion in the first three quarters, against $7.2 billion during the entire previous year. These numbers measure different things: headline totals include conditional milestone payments, while upfront amounts are committed at signing.
Hengrui changes the playbook
In 2023, Hengrui licensed an experimental asthma treatment to Aiolos Bio. In early 2024, GSK acquired Aiolos for $1 billion upfront and up to $400 million tied to regulatory milestones, while assuming certain obligations owed to Hengrui.

















